Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.
Also called NCT02392559
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 158 participants
- Sponsor
- Registry
-
NCT02392559 -
2014-002277-11
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Finland, Greece, Hungary, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Slovenia, South Africa, Spain, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02392559. Randomized; triple masking; primary purpose treatment. Start 2016-03-24 (actual); primary completion 2019-11-25 (actual). Results posted on 2020-07-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
- Acronym
- HAUSER-RCT
- Condition
- Heterozygous Familial Hypercholesterolemia
- Intervention (Drug)
- Evolocumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02392559- Content hash
f2130d903cf68cc628c19ad9339f69070ee3760002a3ef6f4dbfa9c228e56297